Drew Deniger
2022
In 2022, Drew Deniger earned a total compensation of $949.1K as VP, Research and Development at ZIOPHARM Oncology.
Compensation breakdown
| Bonus | $103,672 |
|---|---|
| Option Awards | $481,229 |
| Salary | $345,572 |
| Other | $18,640 |
| Total | $949,113 |
Deniger received $481.2K in option awards, accounting for 51% of the total pay in 2022.
Deniger also received $103.7K in bonus, $345.6K in salary and $18.6K in other compensation.
Rankings
In 2022, Drew Deniger's compensation ranked 3,128th out of 5,672 executives tracked by ExecPay. In other words, Deniger earned more than 44.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,128 out of 5,672 | 45th |
Division Manufacturing | 1,755 out of 3,081 | 43rd |
Major group Chemicals And Allied Products | 826 out of 1,396 | 41st |
Industry group Drugs | 770 out of 1,297 | 41st |
Industry Pharmaceutical Preparations | 559 out of 940 | 41st |
Source: SEC filing on April 25, 2023.
Deniger's colleagues
We found two more compensation records of executives who worked with Drew Deniger at ZIOPHARM Oncology in 2022.